Mesoblast Limited (MESO) vs Sonic Healthcare Limited (SHL.AX)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| MESO | SHL.AX | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Diagnostics & Research |
| Size band | SMALL | MID |
| Listing | Nasdaq GS | ASX |
| Country | Australia | Australia |
| Theme | cell-therapy | diagnostics |
| Price and returns | ||
| Last close | $12.39 | 19.09 AUD |
| Return · 1 week | +3.68% | +1.92% |
| Return · 1 month | −14.55% | +0.42% |
| Return · 3 months | −14.26% | −15.98% |
| Return · year to date | −31.77% | −13.28% |
| Return · 1 year | −25.85% | −9.95% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −42.37% | −21.34% |
| 52-week high | $21.50 | 24.27 AUD |
| 52-week low | $11.89 | 18.11 AUD |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $1.61B | $6.62B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $2.36M | $39.86M |
| Employees | 108 | 47,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 15.42× |
| Price to earnings · forward | 31.41× | 14.49× |
| Price to sales | 15.43× | 0.86× |
| Price to book | 3.26× | 1.12× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 10.90× |
| Enterprise value to revenue | 15.28× | 1.35× |
| PEG ratio | — | 2.30 |
| Earnings per share · trailing | -0.44 | 1.23 |
| Profitability | ||
| Gross margin | 86.14% | 83.53% |
| Operating margin | −33.28% | 9.65% |
| Profit margin | −47.82% | 5.60% |
| Return on equity | −9.86% | 7.50% |
| Return on assets | −4.11% | 3.85% |
| Growth | ||
| Revenue growth | +390.70% | +8.90% |
| Earnings growth | — | +21.60% |
| Balance sheet and payout | ||
| Debt / equity (%) | 22.40 | 68.76 |
| Current ratio | 2.44 | 0.99 |
| Dividend yield | 0.00% | 5.74% |
| Payout ratio | 0.00% | 87.80% |
| Trend and volatility | ||
| RSI · 14 | 35.89 | 53.78 |
| ADX · 14 | 24.55 | 29.40 |
| 50-day average | $15.15 | 19.39 AUD |
| 200-day average | $15.50 | 20.61 AUD |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 4.40% | 1.70% |
The full MESO analysis
Everything this table leaves out for Mesoblast Limited: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the MESO argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full MESO analysisThe full SHL.AX analysis
Everything this table leaves out for Sonic Healthcare Limited: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the SHL.AX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full SHL.AX analysis